SG10201804306VA - THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS - Google Patents
THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONSInfo
- Publication number
- SG10201804306VA SG10201804306VA SG10201804306VA SG10201804306VA SG10201804306VA SG 10201804306V A SG10201804306V A SG 10201804306VA SG 10201804306V A SG10201804306V A SG 10201804306VA SG 10201804306V A SG10201804306V A SG 10201804306VA SG 10201804306V A SG10201804306V A SG 10201804306VA
- Authority
- SG
- Singapore
- Prior art keywords
- thieno
- viral infections
- treatment
- pyrimidines derivatives
- pyrimidines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13178534 | 2013-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201804306VA true SG10201804306VA (en) | 2018-06-28 |
Family
ID=48874951
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201804306VA SG10201804306VA (en) | 2013-07-30 | 2014-07-29 | THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS |
SG11201510736PA SG11201510736PA (en) | 2013-07-30 | 2014-07-29 | THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201510736PA SG11201510736PA (en) | 2013-07-30 | 2014-07-29 | THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS |
Country Status (21)
Country | Link |
---|---|
US (3) | US9556199B2 (zh) |
EP (2) | EP3404031B1 (zh) |
JP (1) | JP6401788B2 (zh) |
KR (1) | KR102322425B1 (zh) |
CN (2) | CN108912137B (zh) |
AU (2) | AU2014298540B2 (zh) |
BR (1) | BR112016001570B1 (zh) |
CA (1) | CA2913691C (zh) |
CL (1) | CL2015003767A1 (zh) |
DK (2) | DK3027624T3 (zh) |
EA (1) | EA036162B1 (zh) |
ES (2) | ES2836881T3 (zh) |
HK (1) | HK1217707A1 (zh) |
IL (2) | IL242872B (zh) |
MX (1) | MX368625B (zh) |
MY (1) | MY179503A (zh) |
PH (1) | PH12015502797B1 (zh) |
SG (2) | SG10201804306VA (zh) |
UA (1) | UA117253C2 (zh) |
WO (1) | WO2015014815A1 (zh) |
ZA (1) | ZA201600655B (zh) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2694484T3 (en) | 2011-04-08 | 2018-11-05 | Janssen Sciences Ireland Uc | PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS |
JP6349256B2 (ja) | 2011-11-09 | 2018-06-27 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染の治療のためのプリン誘導体 |
KR102207888B1 (ko) | 2012-07-13 | 2021-01-26 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염증의 치료를 위한 거대환식 푸린 |
BR112015007586B1 (pt) | 2012-10-10 | 2021-02-09 | Janssen Sciences Ireland Uc | derivados de pirrolo[3,2-d]pirimidina, seu uso e composição farmacêutica que os compreende |
AU2013346793B2 (en) | 2012-11-16 | 2018-03-08 | Janssen Sciences Ireland Uc | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections |
WO2014128189A1 (en) | 2013-02-21 | 2014-08-28 | Janssen R&D Ireland | 2-aminopyrimidine derivatives for the treatment of viral infections |
EP2978429B1 (en) | 2013-03-29 | 2017-02-22 | Janssen Sciences Ireland UC | Macrocyclic deaza-purinones for the treatment of viral infections |
BR112015028890B1 (pt) | 2013-05-24 | 2022-09-20 | Janssen Sciences Ireland Uc | Derivados de piridona, composição farmacêutica que os compreende e uso dos mesmos |
CA2913028C (en) | 2013-06-27 | 2022-03-08 | Janssen Sciences Ireland Uc | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases |
EA036162B1 (ru) * | 2013-07-30 | 2020-10-08 | Янссен Сайенсиз Айрлэнд Юси | Производные тиено[3,2-d]пиримидинов для лечения вирусных инфекций |
RS56787B1 (sr) | 2015-03-04 | 2018-04-30 | Gilead Sciences Inc | Toll-like receptor koji modulira jedinjenja 4,6-diamino-pirido[3,2-d]pirimidina |
US11053256B2 (en) | 2016-07-01 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Dihydropyranopyrimidines for the treatment of viral infections |
US10370342B2 (en) | 2016-09-02 | 2019-08-06 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
ES2826748T3 (es) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll |
US10968184B2 (en) | 2016-09-29 | 2021-04-06 | Janssen Sciences Ireland Unlimited Company | Pyrimidine prodrugs for the treatment of viral infections and further diseases |
EP4234691A3 (en) | 2016-10-14 | 2023-10-18 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
EP3724222A1 (en) | 2017-12-15 | 2020-10-21 | Silverback Therapeutics, Inc. | Antibody construct-drug conjugate for the treatment of hepatitis |
WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
KR102492187B1 (ko) | 2017-12-20 | 2023-01-27 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드 |
CA3091142C (en) | 2018-02-26 | 2023-04-11 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
TW201945003A (zh) * | 2018-03-01 | 2019-12-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 2,4-二胺基喹唑啉衍生物及其醫學用途 |
JP7326319B2 (ja) * | 2018-04-03 | 2023-08-15 | メルク・シャープ・アンド・ドーム・エルエルシー | Stingアゴニストとしてのベンゾチオフェン類及び関連する化合物 |
US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’-環二核苷酸 |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
MX2021002764A (es) | 2018-09-12 | 2021-05-12 | Silverback Therapeutics Inc | Composiciones para el tratamiento de enfermedades con conjugados inmunoestimuladores. |
PT3873903T (pt) | 2018-10-31 | 2024-05-16 | Gilead Sciences Inc | Compostos 6-azabenzimidazol substituídos como inibidores de hpk1 |
TW202136261A (zh) | 2018-10-31 | 2021-10-01 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
WO2020162705A1 (ko) | 2019-02-08 | 2020-08-13 | 성균관대학교산학협력단 | 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도 |
JP7350871B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. | 2’3’-環状ジヌクレオチドおよびそのプロドラッグ |
EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
JP7350872B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. | 3’3’-環状ジヌクレオチドおよびそのプロドラッグ |
TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
CA3141085A1 (en) | 2019-06-19 | 2020-12-24 | Brenda Stevens | Anti-mesothelin antibodies and immunoconjugates thereof |
TW202115056A (zh) | 2019-06-28 | 2021-04-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
CN114269753B (zh) * | 2019-09-29 | 2024-03-05 | 四川科伦博泰生物医药股份有限公司 | 一种含氮并环类化合物,包含其的药物组合物,其制备方法及其用途 |
EP4458975A2 (en) | 2019-09-30 | 2024-11-06 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
WO2021067644A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
WO2021168274A1 (en) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
CN115666637A (zh) | 2020-03-02 | 2023-01-31 | 蛋白科技先锋 | 基于病原体细胞壁骨架的模拟活病原体的纳米粒子及其制备方法 |
TWI845826B (zh) | 2020-03-20 | 2024-06-21 | 美商基利科學股份有限公司 | 4'-c-經取代-2-鹵基-2'-去氧腺苷核苷之前藥及其製造與使用方法 |
WO2022006327A1 (en) | 2020-07-01 | 2022-01-06 | Silverback Therapeutics, Inc. | Anti-asgr1 antibody conjugates and uses thereof |
CN116322751A (zh) | 2020-08-04 | 2023-06-23 | 蛋白科技先锋 | 包含能够动力学控制的佐剂的mRNA疫苗 |
WO2022031011A1 (ko) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | 동력학적으로 작용하는 아주번트 앙상블 |
JP2023536954A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 活性化部位が一時的に不活性化したトール様受容体7または8作用薬と機能性薬物の結合体およびその用途 |
WO2022217022A1 (en) | 2021-04-10 | 2022-10-13 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
CN117203238A (zh) | 2021-04-23 | 2023-12-08 | 普方生物制药美国公司 | Cd70结合剂、其偶联物及其使用方法 |
KR20240006683A (ko) | 2021-05-13 | 2024-01-15 | 길리애드 사이언시즈, 인코포레이티드 | TLR8 조절 화합물과 항-HBV siRNA 치료제의 조합물 |
JP2024522594A (ja) | 2021-06-23 | 2024-06-21 | ギリアード サイエンシーズ, インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
KR20240023629A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
KR20240023628A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2610889B2 (ja) | 1987-09-03 | 1997-05-14 | 日本臓器製薬株式会社 | 新規架橋アデニン誘導体 |
ZA975946B (en) | 1996-07-03 | 1998-04-16 | Japan Energy Corp | Purine derivative. |
EA002769B1 (ru) | 1996-08-28 | 2002-08-29 | Пфайзер Инк. | Замещенные 6,5-гетеробициклические производные |
EP0989129B1 (en) | 1996-10-04 | 2002-12-11 | Kyorin Pharmaceutical Co., Ltd. | Pyrazolopyridylpyridazinone derivatives and process for the preparation thereof |
AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
US6339089B2 (en) * | 1997-08-13 | 2002-01-15 | Fujirebio Inc. | Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same |
AU732361B2 (en) | 1997-11-28 | 2001-04-26 | Dainippon Sumitomo Pharma Co., Ltd. | Novel heterocyclic compounds |
TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
KR20010041015A (ko) | 1998-02-17 | 2001-05-15 | 윌리엄 제이. 리플린 | 항바이러스성 피리미딘 유도체 |
US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
JP4342007B2 (ja) | 1998-08-10 | 2009-10-14 | 大日本住友製薬株式会社 | キナゾリン誘導体 |
JP4315300B2 (ja) | 1998-08-10 | 2009-08-19 | 大日本住友製薬株式会社 | 新規なキナゾリン誘導体 |
US6458798B1 (en) | 1998-08-27 | 2002-10-01 | Sumitomo Pharmaceuticals Company, Limited | Bicyclic pyrimidine compounds and therapeutic use thereof |
US6583148B1 (en) | 1999-04-08 | 2003-06-24 | Krenitsky Pharmaceuticals, Inc. | Neurotrophic substituted pyrimidines |
US6503908B1 (en) | 1999-10-11 | 2003-01-07 | Pfizer Inc | Pharmaceutically active compounds |
WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
WO2003055890A1 (en) * | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
TW200407143A (en) | 2002-05-21 | 2004-05-16 | Bristol Myers Squibb Co | Pyrrolotriazinone compounds and their use to treat diseases |
US7091232B2 (en) | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US7524852B2 (en) | 2002-06-07 | 2009-04-28 | Kyowa Hakko Kogyo Co., Ltd. | Bicyclic pyrimidine derivatives |
AU2003271064B2 (en) | 2002-09-27 | 2010-06-17 | Dainippon Sumitomo Pharma Co., Ltd. | Novel adenine compound and use thereof |
US8455458B2 (en) | 2002-10-16 | 2013-06-04 | Arthrodynamic Technologies, Animal Health Division, Inc. | Composition and method for treating connective tissue damage |
AU2004257149A1 (en) | 2003-06-20 | 2005-01-27 | Coley Pharmaceutical Gmbh | Small molecule toll-like receptor (TLR) antagonists |
AU2004271972B2 (en) | 2003-09-05 | 2010-06-03 | Anadys Pharmaceuticals, Inc. | TLR7 ligands for the treatment of hepatitis C |
EP1728792A4 (en) | 2004-03-26 | 2010-12-15 | Dainippon Sumitomo Pharma Co | 8-OXOADENINE COMPOUND |
ES2563952T3 (es) | 2004-03-26 | 2016-03-16 | Sumitomo Dainippon Pharma Co., Ltd. | Compuesto de 8-oxoadenina 9-sustituido |
WO2007084413A2 (en) | 2004-07-14 | 2007-07-26 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
US7923554B2 (en) | 2004-08-10 | 2011-04-12 | Janssen Pharmaceutica N.V. | HIV inhibiting 1,2,4-triazin-6-one derivatives |
BRPI0517559A (pt) | 2004-11-09 | 2008-10-14 | Hoffmann La Roche | composto, processo para a sua preparação, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de ptb-1b e utilização dos compostos |
US7498409B2 (en) | 2005-03-24 | 2009-03-03 | Schering Corporation | Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists |
JP2008540396A (ja) | 2005-05-04 | 2008-11-20 | ファイザー・リミテッド | 癌およびc型肝炎などのウイルス感染を治療するためのトール様受容体調節薬としての2−アミド−6−アミノ−8−オキソプリン誘導体 |
TW200716631A (en) | 2005-05-12 | 2007-05-01 | Tibotec Pharm Ltd | Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof |
US7994360B2 (en) | 2005-05-16 | 2011-08-09 | Xtl Biopharmaceuticals Ltd. | Benzofuran compounds |
JP4850911B2 (ja) | 2005-09-01 | 2012-01-11 | エフ.ホフマン−ラ ロシュ アーゲー | P2x3およびp2x2/3モジュレーターとしてのジアミノピリミジン |
US20090192153A1 (en) | 2005-09-22 | 2009-07-30 | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan | Novel adenine compound |
WO2007056208A2 (en) * | 2005-11-02 | 2007-05-18 | Cytovia, Inc. | N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
EP1970373A1 (en) | 2005-12-02 | 2008-09-17 | Mitsubishi Tanabe Pharma Corporation | Alicyclic heterocyclic compound |
WO2007093901A1 (en) | 2006-02-17 | 2007-08-23 | Pfizer Limited | 3 -deazapurine derivatives as tlr7 modulators |
WO2008009077A2 (en) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections |
WO2008009078A2 (en) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
EP2114950B1 (en) | 2006-12-07 | 2016-03-09 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
CN103224506A (zh) | 2006-12-20 | 2013-07-31 | P.安杰莱蒂分子生物学研究所 | 抗病毒的吲哚 |
PL2510946T3 (pl) | 2007-02-07 | 2015-12-31 | Univ California | Koniugaty syntetycznych agonistów tlr i ich zastosowania |
JP2008222557A (ja) | 2007-03-08 | 2008-09-25 | Kotobuki Seiyaku Kk | ピロロ[3,2−d]ピリミジン誘導体及びこれを有効成分とする医薬組成物 |
US8067413B2 (en) | 2007-03-19 | 2011-11-29 | Astrazeneca Ab | 9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7 ) modulators |
EP2138497A4 (en) | 2007-03-20 | 2012-01-04 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
TW200902018A (en) | 2007-03-20 | 2009-01-16 | Dainippon Sumitomo Pharma Co | Novel adenine compound |
WO2008147697A1 (en) | 2007-05-22 | 2008-12-04 | Boehringer Ingelheim International Gmbh | Benzimidazolone chymase inhibitors |
AR067182A1 (es) | 2007-06-29 | 2009-09-30 | Gilead Sciences Inc | Moduladores del receptor 7 tipo toll |
MX2010001650A (es) | 2007-08-10 | 2010-08-02 | Glaxosmithkline Llc | Entidades quimicas biciclicas que contienen nitrogeno para el tratamiento de infecciones virales. |
CA2696824A1 (en) | 2007-08-28 | 2009-03-12 | Irm Llc | Compounds and compositions as kinase inhibitors |
WO2009030998A1 (en) | 2007-09-05 | 2009-03-12 | Coley Pharmaceutical Group, Inc. | Pyrimidine compounds as toll-like receptor (tlr) agonists |
PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
CN101910177B (zh) | 2007-12-24 | 2013-08-28 | 泰博特克药品公司 | 作为丙型肝炎病毒抑制剂的大环吲哚 |
CA2713438A1 (en) | 2008-02-07 | 2009-08-13 | The Regents Of The University Of California | Treatment of bladder diseases with a tlr7 activator |
WO2009111337A1 (en) * | 2008-03-03 | 2009-09-11 | Irm Llc | Compounds and compositions as tlr activity modulators |
JP2011518882A (ja) | 2008-04-28 | 2011-06-30 | メルク・シャープ・エンド・ドーム・コーポレイション | Hcvns3プロテアーゼ阻害剤 |
US8946239B2 (en) | 2008-07-10 | 2015-02-03 | Duquesne University Of The Holy Spirit | Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof |
UY31982A (es) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas |
BRPI1010937A2 (pt) | 2009-05-21 | 2019-09-24 | Astrazeneca Ab | composto, uso de um composto, e, método para tratar câncer |
TWI468402B (zh) | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | 降低β-類澱粉生成之化合物 |
US8637525B2 (en) | 2009-07-31 | 2014-01-28 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
US20120232062A1 (en) | 2009-10-20 | 2012-09-13 | Eiger Biopharmaceuticals, Inc. | Azaindazoles to treat flaviviridae virus infection |
EP2491035B1 (en) | 2009-10-22 | 2017-08-30 | Gilead Sciences, Inc. | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
KR101094446B1 (ko) * | 2009-11-19 | 2011-12-15 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 가지는 2,4,7-치환된 티에노[3,2-d]피리미딘 화합물 |
JP2013032290A (ja) | 2009-11-20 | 2013-02-14 | Dainippon Sumitomo Pharma Co Ltd | 新規縮合ピリミジン誘導体 |
DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
WO2012067269A1 (en) | 2010-11-19 | 2012-05-24 | Dainippon Sumitomo Pharma Co., Ltd. | Aminoalkoxyphenyl compounds and their use in the treatment of disease |
WO2012066335A1 (en) | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Phenol compounds als toll -like receptor 7 agonists |
EA201301090A1 (ru) * | 2011-03-30 | 2014-05-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Антидоты антикоагулянтов |
DK2694484T3 (en) | 2011-04-08 | 2018-11-05 | Janssen Sciences Ireland Uc | PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS |
JP6050329B2 (ja) * | 2011-05-18 | 2016-12-21 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染およびその他の疾患を治療するためのキナゾリン誘導体 |
JP6349256B2 (ja) * | 2011-11-09 | 2018-06-27 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染の治療のためのプリン誘導体 |
JP6283320B2 (ja) | 2012-02-08 | 2018-02-21 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染の治療のためのピペリジノ−ピリミジン誘導体 |
DK3459942T3 (da) | 2012-04-24 | 2021-03-08 | Vertex Pharma | DNA-PK-hæmmere |
KR102207888B1 (ko) | 2012-07-13 | 2021-01-26 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염증의 치료를 위한 거대환식 푸린 |
KR102280589B1 (ko) | 2012-08-10 | 2021-07-22 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염 또는 추가 질환의 치료를 위한 알킬피리미딘 유도체 |
EP2712866A1 (en) | 2012-10-01 | 2014-04-02 | Centre National de la Recherche Scientifique (CNRS) | 1,2,4-triazine derivatives for the treatment of viral infections |
ES2701098T7 (es) | 2012-10-05 | 2021-02-03 | Janssen Sciences Ireland Unlimited Co | Derivados de acilaminopirimidina para el tratamiento de infecciones víricas y otras enfermedades |
BR112015007586B1 (pt) | 2012-10-10 | 2021-02-09 | Janssen Sciences Ireland Uc | derivados de pirrolo[3,2-d]pirimidina, seu uso e composição farmacêutica que os compreende |
AU2013346793B2 (en) | 2012-11-16 | 2018-03-08 | Janssen Sciences Ireland Uc | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections |
WO2014128189A1 (en) | 2013-02-21 | 2014-08-28 | Janssen R&D Ireland | 2-aminopyrimidine derivatives for the treatment of viral infections |
EP2978429B1 (en) | 2013-03-29 | 2017-02-22 | Janssen Sciences Ireland UC | Macrocyclic deaza-purinones for the treatment of viral infections |
EA036162B1 (ru) * | 2013-07-30 | 2020-10-08 | Янссен Сайенсиз Айрлэнд Юси | Производные тиено[3,2-d]пиримидинов для лечения вирусных инфекций |
WO2016007966A2 (en) | 2014-07-11 | 2016-01-14 | Northwestern University | 2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase |
-
2014
- 2014-07-29 EA EA201690303A patent/EA036162B1/ru unknown
- 2014-07-29 CN CN201810727533.8A patent/CN108912137B/zh active Active
- 2014-07-29 DK DK14744834.4T patent/DK3027624T3/en active
- 2014-07-29 SG SG10201804306VA patent/SG10201804306VA/en unknown
- 2014-07-29 BR BR112016001570-3A patent/BR112016001570B1/pt not_active IP Right Cessation
- 2014-07-29 CN CN201480042656.8A patent/CN105492446B/zh active Active
- 2014-07-29 SG SG11201510736PA patent/SG11201510736PA/en unknown
- 2014-07-29 EP EP18164850.2A patent/EP3404031B1/en active Active
- 2014-07-29 ES ES18164850T patent/ES2836881T3/es active Active
- 2014-07-29 WO PCT/EP2014/066219 patent/WO2015014815A1/en active Application Filing
- 2014-07-29 MX MX2016001464A patent/MX368625B/es active IP Right Grant
- 2014-07-29 CA CA2913691A patent/CA2913691C/en active Active
- 2014-07-29 EP EP14744834.4A patent/EP3027624B1/en active Active
- 2014-07-29 ES ES14744834T patent/ES2701239T3/es active Active
- 2014-07-29 US US14/908,237 patent/US9556199B2/en active Active
- 2014-07-29 MY MYPI2015003063A patent/MY179503A/en unknown
- 2014-07-29 KR KR1020167002021A patent/KR102322425B1/ko active IP Right Grant
- 2014-07-29 DK DK18164850.2T patent/DK3404031T3/da active
- 2014-07-29 UA UAA201601818A patent/UA117253C2/uk unknown
- 2014-07-29 AU AU2014298540A patent/AU2014298540B2/en not_active Ceased
- 2014-07-29 JP JP2016530483A patent/JP6401788B2/ja active Active
-
2015
- 2015-12-01 IL IL242872A patent/IL242872B/en active IP Right Grant
- 2015-12-16 PH PH12015502797A patent/PH12015502797B1/en unknown
- 2015-12-30 CL CL2015003767A patent/CL2015003767A1/es unknown
-
2016
- 2016-01-29 ZA ZA2016/00655A patent/ZA201600655B/en unknown
- 2016-05-24 HK HK16105881.3A patent/HK1217707A1/zh not_active IP Right Cessation
-
2017
- 2017-01-30 US US15/420,055 patent/US10316043B2/en active Active
-
2018
- 2018-11-01 AU AU2018256591A patent/AU2018256591B2/en not_active Ceased
-
2019
- 2019-05-07 US US16/405,518 patent/US10822347B2/en active Active
- 2019-05-27 IL IL266897A patent/IL266897B/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018256591A1 (en) | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections | |
PH12015501648B1 (en) | 2-aminopyrimidine derivatives for the treatment of viral infections | |
PH12015502780A1 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
PH12015502261A1 (en) | Macrocyclic deaza-purinones for the treatment of viral infections | |
PH12015500983A1 (en) | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections | |
PH12014501738A1 (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
PH12015500758A1 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
PH12015500724B1 (en) | 1, 2, 4-triazine derivatives for the treatment of viral infections | |
PH12015502564B1 (en) | Pyridone derivatives for the treatment of viral infections and further diseases |